AZ spins out antibiotic R&D
03.03.2015 - After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.
The new stand-alone subsidiary company will likely be led by staff from AZ’s Innovative Medicines Unit. It will focus on the research and development of the early-stage antibiotic pipeline, including AZD0914, a novel gyrase inhibitor currently in Phase II for the treatment of gonorrhoea. The currently nameless spin-off will also receive a US$40m investment from AZ as a goodbye gift.
A week ago, industry experts from Fierce reported that AstraZeneca had tried and failed for more than a year to find someone to take over the division. The London-based company has decided to split it off, nevertheless. The move will impact approximately 95 employees based in the US. AZ hopes that some of the researchers impacted by the changes will take up roles in the new company, or in other parts of its own operations. “The decision does not affect the company’s late-stage small molecule infection programmes or MedImmune’s portfolio of biologic anti-infectives,” AZ said in a statement.